布拉氏酵母菌散剂预防支原体肺炎继发腹泻的临床研究

Clinical research of Saccmromyces boulardii powder to prevent diarrhea caused by mycoplasma pneumonia

目的研究布拉氏酵母菌散剂预防支原体肺炎继发腹泻的临床疗效。方法以我院收治的123例支原体肺炎患儿为研究对象,随机分成两组,预防组63例,对照组60例。两组均给予抗肺炎支原体及对症支持等治疗,预防组加服布拉氏酵母菌散剂连续治疗至出院,对比两组患儿住院第4天及第7天继发腹泻的发病率,以及腹泻平均持续时间。结果两组患儿继发腹泻发病率比较差异有统计学意义(χ2=6.34,P<0.05),腹泻平均持续时间预防组为(62.79±7.61)h,对照组为(72.26±16.36)h,两组比较差异有统计学意义(t=2.95,P<0.01)。结论布拉氏酵母菌散剂能够有效降低支原体肺炎继发腹泻的发病率,并能减轻腹泻的严重度,缩短腹泻的持续时间,值得临床推广应用。

Objective To investigate the clinical efficacy of Saccharomyces boulardii powder in the prevention of diarrhea caused by mycoplasma pneumonia. Methods 123 children with mycoplasma pneumonia were randomly divided into two groups. The prevention group had 63 patients, and the control group had 60 patients. All patients were treated with anti-mycoplasma pneumonia and symptomatic and supportive treatment, and the prevention group took Saccharomyces boulardii powder until discharge. The incidence of secondary diarrhea and the average duration of diarrhea and its statistical analysis were analyzed. Results The incidence of diarrhea showed significant difference between the two groups （χ2=6.34, P〈0.05）. The average duration of diarrhea was 62.79±7.61 h in the prevention group, and it was 72.26±16.36 h in the control group （t=2.95, P〈0.01）. Conclusion Saccharomyces boulardii powder can effectively reduce the incidence of mycoplasma pneumonia secondary to diarrhea, and it can reduce the severity of diarrhea and shorten the duration of diarrhea, which is worthy of clinical application.